Home
OE Originals
OE Insights
CME
All Specialties
Arthroplasty
Cannabis
Ev. Based Medicine
Foot & Ankle
General Orthopaedics
Hand & Wrist
Metabolic Disorders
Osteoarthritis
Pediatric Orthopaedics
Peri-Operative
Phys. Therapy & Rehab
Shoulder & Elbow
Spine
Sports Medicine
Trauma
Tumour

Author Interviews

Conference Reports

PeerView

All Videos
(210 Videos)

Education
(4 Videos)
Innovation
(4 Videos)
Leadership
(21 Videos)
Personal Growth
(3 Videos)
Practice
(55 Videos)
Research
(29 Videos)
OrthoJoe
(76 Videos)
Webinar
(9 Videos)
OE Headline
(7 Videos)
OrthoPod
(1 Videos)

COVID-19 Resource Center

OE World Tour

OE Perspectives

OE Ideas

OE Recommends

To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover
General Orthopaedics

No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
April 2021
General Orthopaedics High Impact Icon

No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients

Vol: 20| Issue: 1| Number:4| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

N Engl J Med. 2021 Mar 11;384(10): 905-914.

Contributing Authors:
Group ACTIV-3/TICO LY-CoV555 Study JD Lundgren B Grund CE Barkauskas TL Holland RL Gottlieb U Sandkovsky SM Brown KU Knowlton WH Self DC Files MK Jain T Benfield ME Bowdish BG Leshnower JV Baker JU Jensen EM Gardner AA Ginde ES Harris IS Johansen N Markowitz MA Matthay L √òstergaard CC Chang VJ Davey A Goodman ES Higgs DD Murray TA Murray R Paredes MKB Parmar AN Phillips C Reilly S Sharma RL Dewar M Teitelbaum D Wentworth H Cao P Klekotka AG Babiker AC Gelijns VL Kan MN Polizzotto BT Thompson HC Lane JD Neaton

Synopsis

Three hundred and fourteen hospitalized patients with COVID-19 were randomized to receive a single intravenous infusion of LY-CoV555 antibody therapy (n=163) or placebo (n=151) for the improvement of recovery and reduction of adverse events. The primary outcomes of interest was sustained recovery (discharged home and remaining at home for at lest 14 days) and a composite safety outcome of death, s...

To view the full content, login to your account,
or start your 30-day FREE Trial today.

FREE TRIAL Forgot Password?

Explore some of our unlocked ACE Reports below!

 Treatment of osteoarthritis: A role for education programmes?
The prevalence of intimate partner violence in women presenting to orthopaedic clinics
Osteoporosis Choice decision aid improves treatment experience of clinicians and patients
Protein-Rich nutritional supplementation shows limited efficacy in elderly hip fractures
Ace Report Preview Image

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue